TABLE 2.
Demographics of patients prescribed new diabetes drugs in Japan, January 2011‐December 2015
| Ipragliflozin | Dapagliflozin | Luseogliflozin | Tofogliflozin | Canagliflozin | Empagliflozin | Dulaglutide | Exenatide | |
|---|---|---|---|---|---|---|---|---|
| N | 390,778 | 306,257 | 167,649 | 217,154 | 222,021 | 232,433 | 132,049 | 22,197 |
| Male (%) | 238,485 (61.0) | 189,311 (61.8) | 101,551 (60.6) | 131,872 (60.7) | 139,938 (63.0) | 151,509 (65.2) | 73,205 (55.4) | 11,750 (52.9) |
| Age, y (SD) | 59.3 (12.5) | 59.4 (12.4) | 60 (12.5) | 59.1 (12.5) | 59.6 (12.5) | 60.4 (12.7) | 65.3 (14.4) | 63.2 (15.2) |
| First prescription overall a | 2014/4 | 2014/5 | 2014/5 | 2014/5 | 2014/9 | 2015/2 | 2015/9 | 2013/5 |
| First prescription in the slowest prefecture a | 2014/4 | 2014/5 | 2014/5 | 2014/5 | 2014/9 | 2015/3 | 2015/11 | 2013/6 |
| Indication | Type I and II diabetes | Type II diabetes | ||||||
a
Data are shown as year/month.